Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Baseline Immunoglobulin G and Immune Function in Lymphoma: A Retrospective Analysis

Christopher Grant, Danielle Brazel, Lauren C. Pinter-Brown

Blood (2023) 142 (Supplement 1): 1749.

https://doi.org/10.1182/blood-2023-187540

Published: 2023

Journal Articles

A Phase 1 Study of Adding Pitavastatin to Venetoclax-Based Therapy in AML and CLL/SLL

Elizabeth A. Brem, Susan M. O'Brien, Pamela S. Becker, Deepa Jeyakumar, Lauren C. Pinter-Brown, Christina Kirk, Thomas Taylor, Blake Johnson, Stephanie Osorio, Roberta Buono, David A Fruman

Blood (2023) 142 (Supplement 1): 5940.

https://doi.org/10.1182/blood-2023-188086

Published: 2023

Journal Articles

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Blood (2023) 142 (Supplement 1): 3081.

https://doi.org/10.1182/blood-2023-181130

Published: 2023

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

Eric D Jacobsen, Pier Luigi Zinzani, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Marci Daugherty, Jonathan E Brammer, Neha Mehta-Shah, Barbara Pro, Steven M. Horwitz

Blood (2022) 140 (Supplement 1): 9387–9389.

https://doi.org/10.1182/blood-2022-169432

Published: 2022

Journal Articles

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Rashmi Khanal, Jennifer N. Saultz, Umar Farooq, Sunita Nathan, Amitkumar Mehta, Ayad Hamdan, Lawrence E. Morris, Jr., Houston Holmes, Lauren C. Pinter-Brown, John K.C. Lim, Amanda Conerty, Heather Raymon, Peter Flynn, Anita G. Seto, Joseph J. Maly

Blood (2022) 140 (Supplement 1): 12742–12743.

https://doi.org/10.1182/blood-2022-159282

Published: 2022

Journal Articles

JAK/STAT: a pathway through the maze of PTCL?

Lauren C. Pinter-Brown

Blood (2021) 138 (26): 2747–2748.

https://doi.org/10.1182/blood.2021014238

Published: 2021

Journal Articles

First-Line Treatment with R-CHOP Vs Dose-Adjusted R-EPOCH for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Tamer Othman, Juan Penaloza, Elizabeth A Brem, Lauren C. Pinter-Brown, Abinav Baweja, Matthew Hyun Joon Lee, Jane Ly, Jack Reid, Haifaa Abdulhaq, Daria Gaut, Caspian Oliai, Erin G. Reid, Joseph M Tuscano

Blood (2021) 138 (Supplement 1): 2509.

https://doi.org/10.1182/blood-2021-151374

Published: 2021

Journal Articles

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Swaminathan P. Iyer, MD, Brad M. Haverkos, MDMPH,MS, Jasmine Zain, MD, Radhakrishnan Ramchandren, MD, Mary Jo Lechowicz, MD, Sumana Devata, MD, Neil Korman, MD, Lauren C. Pinter-Brown, MD, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD, Auris Huen, MD

Blood (2019) 134 (Supplement_1): 2831.

https://doi.org/10.1182/blood-2019-123954

Published: 2019

Journal Articles

Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

Swami P. Iyer, MD, Auris Huen, MD, Andres J M Ferreri, MD, Bradley M. Haverkos, MD MPH, MS, Jasmine M. Zain, MD, Radhakrishnan Ramchandren, MD, Mary Jo Lechowicz, MD, Sumana Devata, MD, Neil Korman, MD, Lauren C. Pinter-Brown, MD, Richard Delarue, MD, Kasi V Routhu, PhD, Prajak Barde, MD, Ajit M Nair, PhD, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 2925.

https://doi.org/10.1182/blood-2018-99-112757

Published: 2018

Journal Articles

Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry

Robert Stuver, MD, Niloufer Khan, MD, Marc Schwartz, Mark Acosta, Massimo Federico, MD, Christian Gisselbrecht, Frederick Lansigan, MD, Lauren C. Pinter-Brown, MD, Barbara Pro, MD, Andrei R. Shustov, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Salvia Jain, MD

Blood (2018) 132 (Supplement 1): 2926.

https://doi.org/10.1182/blood-2018-99-112869

Published: 2018

Journal Articles

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Blood (2018) 132 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2018-99-112847

Published: 2018

Journal Articles

Phase 1 Study of the Safety and Efficacy of MRG-106, a Synthetic Inhibitor of microRNA-155, in CTCL Patients

Blood (2017) 130 (Supplement 1): 820.

https://doi.org/10.1182/blood.V130.Suppl_1.820.820

Published: 2017

Journal Articles

The Role of Upfront Hematopoietic Stem Cell Transplantation (HSCT) in Peripheral T-Cell Lymphoma (PTCL) Patients in Complete Remission (CR) with a Special Focus on Nodal PTCL: Report from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a Prospective Multicenter Cohort Study

Blood (2017) 130 (Supplement 1): 342.

https://doi.org/10.1182/blood.V130.Suppl_1.342.342

Published: 2017

Journal Articles

Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study

Frederick Lansigan, MD, Steven M Horwitz, MD, Lauren C Pinter-Brown, MD, Kenneth R Carson, MD, Andrei R Shustov, MD, Steven T. Rosen, MD, Barbara Pro, MD, Eric D. Hsi, MD, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A Bellm, MIM, Mark Acosta, PharmD, Francine M. Foss, MD

Blood (2016) 128 (22): 4150.

https://doi.org/10.1182/blood.V128.22.4150.4150

Published: 2016

Journal Articles

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

Madeleine Duvic, Lauren C. Pinter-Brown, Francine M. Foss, Lubomir Sokol, Jeffrey L. Jorgensen, Pramoda Challagundla, Karen M. Dwyer, Xiaoping Zhang, Michael R. Kurman, Rocco Ballerini, Li Liu, Youn H. Kim

Blood (2015) 125 (12): 1883–1889.

https://doi.org/10.1182/blood-2014-09-600924

Published: 2015

Journal Articles

Phase II Preliminary Results of SGN-30 (Anti-CD30 mAb) in Patients with CD30+ Lymphoproliferative Disorders.

Madeleine Duvic, MD, Youn Kim, MD, Sunil Reddy, MD, Andres Forero-Torres, MD, Lauren C. Pinter-Brown, MD, Mark U. Rarick, MD, John Zic, MD, Sophie Worobec, MD, Neil Korman, MD, Timothy Kuzel, MD, Kimberly Bohjanen, MD, Karen Flessland, Jeremy Barton, MD, Eric Sievers, MD

Blood (2006) 108 (11): 2733.

https://doi.org/10.1182/blood.V108.11.2733.2733

Published: 2006

Journal Articles

Preliminary Phase II Results of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Cutaneous Anaplastic Large Cell Lymphoma (ALCL).

Madeleine Duvic, MD, Joy Kunishige, MD, Youn H. Kim, MD, Andres Foreno-Torres, MD, Lauren C. Pinter-Brown, MD, Mark U. Rarick, MD, John Zic, MD, Sophie M. Worobec, MD, Francine Foss, MD, Karen Flessland, Jeremy Barton, MD

Blood (2005) 106 (11): 4802.

https://doi.org/10.1182/blood.V106.11.4802.4802

Published: 2005

NARROW

Baseline Immunoglobulin G and Immune Function in Lymphoma: A Retrospective Analysis

A Phase 1 Study of Adding Pitavastatin to Venetoclax-Based Therapy in AML and CLL/SLL

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

JAK/STAT: a pathway through the maze of PTCL?

First-Line Treatment with R-CHOP Vs Dose-Adjusted R-EPOCH for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Phase 1 Study of the Safety and Efficacy of MRG-106, a Synthetic Inhibitor of microRNA-155, in CTCL Patients

Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

Phase II Preliminary Results of SGN-30 (Anti-CD30 mAb) in Patients with CD30+ Lymphoproliferative Disorders.

Preliminary Phase II Results of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Cutaneous Anaplastic Large Cell Lymphoma (ALCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only